This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07868835 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Viking Therapeutics, Inc. |
| Enrollment | 560 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Weight Loss |
| Interventions | VK2735; Placebo comparator |
| Start | Nov 2026 |
| Primary completion | Jul 2028 |
| Study completion | Aug 2028 |
| Results posted | Not yet |
| Registry last updated | Nov 16, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage change in body weight for participants receiving VK2735 orally once daily | 68 weeks |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of VK2735
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) (Phase 3 NCT07868939)
- VANQUISH 2: VK2735, Phase 3 (NCT07104383)
- VK2735 for Weight Management Phase 3 (Phase 3 NCT07104500)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.